# A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

> **NCT05458297** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 223 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Richter Transformation Lymphoma

## Interventions

- **BIOLOGICAL:** Zilovertamab vedotin
- **DRUG:** Nemtabrutinib

## Key facts

- **NCT ID:** NCT05458297
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-21
- **Primary completion:** 2029-05-17
- **Final completion:** 2029-05-17
- **Target enrollment:** 223 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458297, "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05458297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*